

Design of a Cholic Acid-based Triarmed Star Polymer Network for Targeted and Sustained Drug Delivery for Melanoma Treatment

Souvik Chowdhury¹, Swapan Maity¹, Hitesh Harsukhbhai Chandpa², Alok Kumar¹, Rohan Chand Sahu², Jairam Meena², Ashish Kumar Agrawal² and Pralay Maiti^{*, 1}

¹School of Materials Science and Technology, Indian Institute of Technology
(Banaras Hindu University), Varanasi 221005, India

² Department of Pharmaceutical Engineering and Technology, Indian Institute of
Technology (Banaras Hindu University), Varanasi 221005, India

Correspondence may be made to P. Maiti (pmaiti.mst@itbhu.ac.in)




Figure S1 :a) and b) Magnified NMR spectra of PP, CP1 and CP2. c) GPC chromatograms of PP, CP1, and CP2, illustrating the molecular weight distribution and shift upon chain extension and modification; d) Summary of molecular characteristics, including number-average molecular weight (M_n), weight-average molecular weight (M_w), and polydispersity index (\mathcal{D}) for PP, CP1, and CP2, highlighting the impact of structural modification on polymer uniformity and size distribution.




Figure S2: Elemental composition analysis of PP, CP1, and CP2 performed using EDAX, highlighting the presence and relative abundance of key elements, and confirming successful incorporation of functional components during polymer modification.




Figure S3: **a)** Height Profile (Cross-Sectional Roughness) of PP , CP1 and CP2. **b)** Topography Histogram (Distribution of Surface Heights) of PP, CP1 and CP2 obtained from AFM.





Figure S4 : Comprehensive analysis of the thermal and mechanical behavior of PP, CP1, and CP2 formulations. **a–b)** Shift factor (aT) plots for PP and CP2, demonstrating minimal deviation on either side of 160 °C, indicating thermorheological stability and consistent viscoelastic response across a temperature range;; **c–f)** Comparative mechanical analysis based on tensile stress–strain data, including: **c)** Toughness, **d)** Tensile strength, **e)** Elongation at break,, and **f)** Elastic modulus, demonstrating the influence of structural modifications on the overall mechanical performance of the materials.


a)

Sample	Zero order Model	First order Model	Krosmeyer Peppas model	Higuchi model
PP@Dox	Slope=0.56 Intercept=1.22 R ² (COD)=0.86	Slope=0.05 Intercept=0.13 R ² (COD)=0.89	Slope=0.34 Intercept=0.44 R ² (COD)=0.959	Slope=1.8 Intercept=0.93 R ² (COD)=0.966
CP1@Dox	Slope=0.30 Intercept=1.63 R ² (COD)=0.856	Slope=0.046 Intercept=0.26 R ² (COD)=0.853	Slope=0.24 Intercept=0.34 R ² (COD)=0.989	Slope=1.0 Intercept=1.07 R ² (COD)=0.969
CP2@Dox	Slope=0.25 Intercept=1.93 R ² (COD)=0.91	Slope=0.065 Intercept=0.33 R ² (COD)=0.74	Slope=0.26 Intercept=0.22 R ² (COD)=0.983	Slope=0.79 Intercept=0.79 R ² (COD)=0.988

b)



c)



d)




Figure S5: To elucidate the drug release behavior of the formulations, the release kinetics of Doxorubicin from PP@Dox, CP1@Dox, and CP2@Dox were systematically analyzed using various mathematical models. **a)** Summary table presenting a comparative overview of the fitting parameters and correlation coefficients for each kinetic model applied; **b)** Zero-order release model, depicting a constant drug release rate over time, independent of concentration; **c)** First-order release model, illustrating concentration-dependent release kinetics; **d)** Korsmeier–Peppas model, providing insight into the release mechanism and diffusion behavior through the polymer matrices.




Figure S6: Evaluation of biocompatibility, in vitro cytotoxicity, and intracellular trafficking of prepolymer (PP) and cholic acid-modified polymers (CP1 and CP2), using cancerous (SiHa) and normal (3T3-L1) cell lines. **a)** MTT-based cell viability assay assessing the cytotoxic effects of PP, CP1, and CP2 (20 $\mu\text{g}/\text{mL}$) on SiHa cells. The results indicate significantly improved anti-cancer activity for the CP2 ; **b)** Fluorescence microscopy images of SiHa cells stained with acridine orange/ethidium bromide (AO/EtBr) following treatment with PP, CP1, and CP2 (all at 20 $\mu\text{g}/\text{mL}$), highlighting live and apoptotic/dead cells. Images captured at 40 \times magnification; **c)** In vitro biocompatibility analysis of PP, CP1, and CP2 (20 $\mu\text{g}/\text{mL}$) on 3T3-L1 fibroblast cells over different incubation periods. ; **d)** Intracellular trafficking study in cancer cells treated with CP1@Dox, tracked using LysoTracker Green (100 nM) for endo/lysosomal compartments and DAPI (5 $\mu\text{g}/\text{mL}$) for nuclear staining at various time

points. Fluorescence images acquired at 40× magnification. Data are expressed as mean \pm SD (n = 3); statistical significance indicated as *p < 0.05, **p < 0.01, ***p < 0.001




Figure S7: In vitro cellular evaluation of prepolymer (PP) and cholic acid-modified ppolymers (CP1 and CP2), emphasizing cellular uptake and adhesion behavior in cancer cells. **a)** Fluorescence microscopy images showing the internalization of free Dox, PP@Dox, and CP2@Dox (20 μg/mL) in cancer cells after 6 hours of incubation. Differences in fluorescence intensity reveal variation in cellular uptake efficiency among the formulations. Images captured at 40× magnification; **b)** Phase-contrast microscopy illustrating the morphology of SiHa cells cultured on surfaces treated with PP, CP1, and CP2 (20 μg/mL) after 24 hours. Distinct cellular responses indicate varying degrees of interaction with each formulation; **c)** Quantitative analysis of cell adhesion, presenting the percentage of cancer cells adhering to PP, CP1, and CP2-treated surfaces after 24 hours. CP2-treated surfaces exhibit significantly enhanced adhesion, suggesting superior cell-material affinity. Data are expressed as mean \pm SD (n = 3); statistical significance indicated as *p < 0.05, **p < 0.01, ***p < 0.001




Figure S8: Zeta Potential of CP2 and CP2@Dox